Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 313c; offers guidance

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q1 EPS of $1.68, $3.13 worse than the analyst estimate of $4.81. Revenue for the quarter came in at $897.84 million versus the consensus estimate of $983.86 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2025 EPS of $4.00-$5.60, versus the consensus of $23.23. Jazz Pharmaceuticals sees FY2025 revenue of $4.15-4.4 billion, versus the consensus of $4.29 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• Stay long AI-capex winners into the peak, Stifel says despite bubble fears
• Aspire Biopharma lists caffeine stick packs on Amazon
• LENZ Therapeutics licenses VIZZ eye drop to Arrotex for Australia, NZ